Table 2. Associations between tagging SNPs in WNT2B and BTRC of the Wnt pathway and CMSS of CM patients in the MDACC Study and the Harvard study.
| Genotype | MDACC study | Harvard study | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||
| All | Death (%) | HR (95% CI)1 | P1 | All | Death (%) | HR (95% CI)2 | P2 | |
| WNT2B | ||||||||
| rs1175649 | ||||||||
| GG | 682 | 68 (10.0) | 1.0 0 | 321 | 32 (10.0) | 1.0 0 | ||
| GT | 171 | 27 (15.8) | 2.11 (1.32-3.38) | 0.002 | 85 | 14 (16.5) | 1.76 (0.94-3.29) | 0.079 |
| TT | 5 | 0 (0.0) | -- | -- | 3 | 2 (66.7) | 7.02 (1.62-30.30) | 0.009 |
| Trend test | 1.97 (1.26-3.09) | 0.003 | 2.03 (1.19-3.46) | 0.010 | ||||
| GT+TT vs GG | 2.08 (1.30-3.33) | 0.002 | 1.93 (1.06-3.53) | 0.031 | ||||
| BTRC | ||||||||
| rs61873997 | ||||||||
| GG | 367 | 52 (14.2) | 1.0 0 | 171 | 29 (17.0) | 1.0 0 | ||
| GA | 391 | 37 (9.5) | 0.60 (0.39-0.93) | 0.022 | 182 | 14 (7.7) | 0.44 (0.23-0.83) | 0.011 |
| AA | 100 | 6 (6.0) | 0.45 (0.19-1.07) | 0.070 | 56 | 5 (8.9) | 0.50 (0.19-1.29) | 0.152 |
| Trend test | 0.62 (0.44-0.87) | 0.006 | 0.58 (0.37-0.92) | 0.021 | ||||
| GA+AA vs GG | 0.57 (0.38-0.87) | 0.009 | 0.45 (0.25-0.81) | 0.007 | ||||
Abbreviations: SNP, single-nucleotide polymorphism; CMSS, cutaneous melanoma-specific survival; CM, cutaneous melanoma; MDACC, MD Anderson Cancer Center; HR: hazards ratio; CI: confidence interval.
1
Adjusted for age, sex, Breslow thickness, regional/distant metastasis, ulceration of tumor and tumor cell mitotic rate.
2
Adjusted for age and sex.